MedTrace Logo

A Study to Evaluate the Safety and Efficacy of AV-1 Against Dengue Virus 3 (DENV-3) Infection

NCT06799741 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 85

Last updated 2026-03-31

No results posted yet for this study

Summary

The goal of this clinical trial is to determine the prophylactic and therapeutic effect of AV-1 in healthy adults using a DENV-3 controlled human infection model (CHIM)

Conditions

  • DENV-3 Controlled Human Infection Model

Interventions

DRUG

AV-1 100 mg

human monoclonal antibody (mAb) intravenous solution or

DRUG

AV-1 300 mg

human monoclonal antibody (mAb) intravenous solution or

DRUG

AV-1 900 mg

human monoclonal antibody (mAb) intravenous solution or

DRUG

Placebo

(0.9% saline intravenous solution) 12:2

Sponsors & Collaborators

  • AbViro LLC

    lead INDUSTRY

Principal Investigators

  • Urban Ramstedt, PhD · AbViro LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-01-07
Primary Completion
2026-03-11
Completion
2026-03-11
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06799741 on ClinicalTrials.gov